Evommune (EVMN) Total Liabilities (2024 - 2026)

Evommune (EVMN) has 3 years of Total Liabilities data on file, last reported at $17.9 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $17.9 million, down 88.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.9 million (down 88.69% YoY), and the FY2025 annual result was $19.4 million, down 32.04% from the prior year.
• Total Liabilities declined to $17.9 million in Q1 2026 per EVMN's latest filing, from $19.4 million in the prior quarter.
• Over five years, Total Liabilities peaked at $158.2 million in Q1 2025 and troughed at $10.7 million in Q3 2025.
• A 3-year average of $59.5 million and a median of $23.9 million in 2024 frame the typical range for Total Liabilities.
• On a YoY basis, Total Liabilities climbed as much as 32.04% in 2025 and fell as far as 91.29% in 2025.
• A 3-year view of Total Liabilities shows it stood at $28.5 million in 2024, then tumbled by 32.04% to $19.4 million in 2025, then slipped by 7.64% to $17.9 million in 2026.
• Business Quant data shows EVMN's Total Liabilities at $17.9 million in Q1 2026, $19.4 million in Q4 2025, and $10.7 million in Q3 2025.